Segmentectomy for Solid-dominant Lung Cancer

Launched by FUDAN UNIVERSITY · Oct 9, 2024

Keywords

ClinConnect Summary

This clinical trial, called ECTOP-1025, is looking at a type of surgery called segmentectomy for patients with a specific kind of lung cancer known as solid-dominant invasive lung adenocarcinoma. The main goal of the study is to find out how well this surgery works in helping patients stay free of the disease for at least five years, and to see how it affects patients' lung function after the surgery.

To participate, patients need to be between 18 and 80 years old and must not have had previous lung cancer surgeries or treatments like chemotherapy or radiation. They should have a tumor that is between 2 and 3 centimeters in size, with certain characteristics that make it suitable for this type of surgery. Participants can expect to undergo the segmentectomy procedure and will be monitored closely for their recovery and health outcomes over time. This trial is currently recruiting participants, and it offers an opportunity to contribute to important research in lung cancer treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients who sign the informed consent form and are willing to complete the study according to the plan;
• • Aged from 18 to 80 years old;
• • ECOG equals 0 or 1;
• • Not receiving lung cancer surgery before;
• • Confirmed to be invasive lung adenocarcinoma intraoperatively or postoperatively;
• • Ground glass-dominant lung nodules
• • Consolidation-to-tumor ratio (CTR) ranges from 0.5 to 1, and tumor size ranges from 2 to 3cm;
• • cN0 without distant metastasis;
• • Tumors could be completely resected assed by surgeons;
• • Not receiving chemotherapy or radiotherapy before.
• Exclusion Criteria:
• • CTR is not 0.5-1, or size is not 2-3cm;
• • Tumors could not be completely resected assed by surgeons;
• • Not lung adenocarcinoma diagnosed cytologically or pathologically;
• • Receiving lung cancer surgery before;
• • Receiving radiotherapy or chemotherapy.